Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Oct 15;89(20):9784-8.
doi: 10.1073/pnas.89.20.9784.

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

Affiliations

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

R O Williams et al. Proc Natl Acad Sci U S A. .

Abstract

There is considerable evidence implicating tumor necrosis factor alpha (TNF-alpha) in the pathogenesis of rheumatoid arthritis. This evidence is based not only on the universal presence of TNF-alpha in arthritic joints accompanied by the upregulation of TNF-alpha receptors but also on the effects of neutralizing TNF-alpha in joint cell cultures. Thus, neutralization of TNF-alpha in vitro results in inhibition of the production of interleukin 1, which like TNF-alpha, is believed to contribute to joint inflammation and erosion. To determine the validity of this concept in vivo, the effect of administering TNF-neutralizing antibodies to mice with collagen-induced arthritis has been studied. This disease model was chosen because of its many immunological and pathological similarities to human rheumatoid arthritis. TN3-19.12, a hamster IgG1 monoclonal antibody to murine TNF-alpha/beta, was injected i.p. into mice either before the onset of arthritis or after the establishment of clinical disease. Anti-TNF administered prior to disease onset significantly reduced paw swelling and histological severity of arthritis without reducing the incidence of arthritis or the level of circulating anti-type II collagen IgG. More relevant to human disease was the capacity of the antibody to reduce the clinical score, paw swelling, and the histological severity of disease even when injected after the onset of clinical arthritis. These results have implications for possible modes of therapy of human arthritis.

PubMed Disclaimer

References

    1. J Immunol Methods. 1992 Feb 14;147(1):93-100 - PubMed
    1. Arthritis Rheum. 1983 Sep;26(9):1120-31 - PubMed
    1. EMBO J. 1991 Dec;10(13):4025-31 - PubMed
    1. Arthritis Rheum. 1991 Sep;34(9):1125-32 - PubMed
    1. Scand J Immunol. 1990 Feb;31(2):147-57 - PubMed

Publication types

MeSH terms